Outpatiented · Case Knowledge
A patient post-ablation on flecainide develops perioral and facial numbness along with chest pain. The pharmacist suggests halving the dose. The EKG was normal at one point. This presentation has a specific name, a specific mechanism, and a specific level of urgency that is not reflected in 'try cutting the dose.'
What Flecainide Does
Flecainide is a Class IC antiarrhythmic drug. It works by blocking sodium channels in the heart, slowing conduction and suppressing arrhythmia triggers. It is used for atrial fibrillation and atrial flutter, often post-ablation when breakthrough arrhythmia remains a concern.
The same sodium channel blockade that makes it effective also produces toxicity when levels rise too high or when individual sensitivity is exceeded. Sodium channel blockade in the central nervous system produces the neurological symptoms. Sodium channel blockade in cardiac tissue produces QRS widening, conduction slowing, and, most dangerously, pro-arrhythmia.
Flecainide has a narrow therapeutic index. The therapeutic range is 0.2 to 1.0 mcg/mL. Toxicity becomes more likely above 1.0, but symptoms can appear within the therapeutic range in sensitive individuals or those with altered clearance.
Renal function is the critical clearance variable. Flecainide is significantly renally cleared. A patient with even mild renal impairment can accumulate flecainide over time even on an apparently stable dose, crossing from therapeutic into toxic range without any change in prescription.
The drug that controls the arrhythmia
can cause a worse one if levels go too high.
The Toxicity Picture
Flecainide toxicity manifests in two systems. The CNS symptoms typically appear first and serve as a warning. The cardiac manifestations are what make the toxicity potentially life-threatening.
The CAST trial (Cardiac Arrhythmia Suppression Trial) was a landmark study that had to be stopped early because flecainide and encainide, both Class IC agents, were found to increase mortality in patients with structural heart disease and prior myocardial infarction. The drugs that suppressed PVCs also caused lethal arrhythmias in patients with underlying cardiac substrate.
This is why flecainide is generally avoided in patients with structural heart disease, reduced ejection fraction, or coronary artery disease. Post-ablation patients may have a modified cardiac substrate, and the ongoing necessity of flecainide versus rate control alone is a conversation that should happen with the electrophysiologist, especially when toxicity symptoms are present.
Monomorphic VT induced by flecainide is a recognized complication. It is often sustained and hemodynamically significant. The treatment for severe flecainide cardiac toxicity is intravenous sodium bicarbonate, the same mechanism used in tricyclic antidepressant overdose, because providing extra sodium ions can partially overcome the channel blockade.
Why the Normal EKG Is Not Reassuring
A single normal EKG at a clinic visit or urgent care does not rule out flecainide toxicity for a specific reason: the cardiac EKG findings. QRS widening, PR prolongation, are concentration-dependent and fluctuate with blood levels.
Flecainide levels vary throughout the day depending on dosing timing, absorption, and individual pharmacokinetics. An EKG drawn at a moment when levels are lower in their daily cycle can appear completely normal. An EKG drawn at peak levels may show clear QRS widening. The EKG needs to be obtained at the right time relative to dosing, ideally at or near peak levels, and interpreted in the context of the patient's prior baseline EKGs to detect subtle change.
The neurological symptoms, perioral numbness, dizziness, track more closely with level fluctuations and can be present even when a spot EKG looks normal. Their presence is the clinical signal. Waiting for EKG confirmation before acting on neurological toxicity symptoms is the wrong approach.
A normal EKG between events
is not the same as the drug being safe at this dose.
Right Next Steps and Alternatives
The immediate priority is contact with the prescribing electrophysiologist or cardiologist today. This is not an emergency requiring the ER right now, unless chest pain worsens or becomes sustained, but it is not a situation that can wait for a routine appointment.
A serum flecainide level is a routine test. Therapeutic range is 0.2 to 1.0 mcg/mL. Levels above 1.0 mcg/mL correlate with increased toxicity risk, though symptoms can occur within range in sensitive patients. Checking the level gives the electrophysiologist objective data for the dose adjustment conversation. It should be drawn at a consistent time relative to dosing.
Flecainide is significantly renally cleared. Even mild renal impairment, a GFR reduction that might not seem clinically relevant in other contexts, can lead to drug accumulation over time. A patient whose renal function has declined modestly since flecainide was initiated may have drifted into a toxic range on an unchanged dose. BMP or CMP with creatinine and GFR estimation is a necessary part of this evaluation.
If the dose is adjusted, a repeat EKG at steady state on the new dose is standard, looking specifically at QRS duration and PR interval compared to the prior baseline. QRS widening of more than 25% from baseline is a warning sign that conduction is being significantly suppressed. This comparison requires having the baseline EKG. If no baseline exists, getting one now establishes the reference point.
Post-ablation, if the procedure was successful and the patient is in stable sinus rhythm, rate control alone, with a beta blocker or calcium channel blocker, may be all that is needed. The antiarrhythmic was initiated in a specific clinical context. That context may have changed. The electrophysiologist should address whether flecainide is still necessary given the current arrhythmia status and the toxicity symptoms now present.
The Class III antiarrhythmics are the next consideration: sotalol (available outpatient, requires QTc monitoring), dofetilide (effective but requires inpatient initiation with continuous QT monitoring for the first three days), dronedarone (less toxic than amiodarone, appropriate if no heart failure), and amiodarone (most effective, last line due to toxicity profile including thyroid, pulmonary, and hepatic effects). Choice depends on ejection fraction, renal function, QTc, and arrhythmia burden.
Questions People Actually Ask
What does flecainide toxicity feel like?
The most characteristic early symptom is perioral numbness, tingling or numbness around the mouth and lips. Facial numbness extending beyond the perioral area is also reported. This is a CNS manifestation of sodium channel blockade in neural tissue and is specific enough to flecainide toxicity that its presence on this medication should prompt immediate medical contact.
Other CNS symptoms include dizziness, visual disturbances (blurred or double vision), headache, and tremor. In severe toxicity: seizures and loss of consciousness. Cardiac symptoms, chest pain, palpitations, awareness of slow or irregular heartbeat, may accompany or follow the neurological symptoms. The combination of perioral numbness and chest pain on flecainide is a specific toxicity presentation, not a coincidence.
Can I just cut my flecainide dose in half on my own?
Halving the dose without medical oversight is not the right approach, even though it is reasonable as a very short-term step while arranging contact with your prescribing physician. The issue is that flecainide dose adjustments need to be followed with a repeat EKG at the new dose to assess QRS widening and PR interval, changes that indicate how much the drug is suppressing cardiac conduction.
Additionally, if renal function has declined and is driving the toxicity, a dose reduction alone may not resolve the accumulation problem, the underlying clearance issue needs to be addressed.
Do not stop flecainide abruptly without guidance. Sudden discontinuation can trigger rebound arrhythmia in patients who are dependent on it for rhythm control. Contact the prescribing electrophysiologist or cardiologist today, not next week.
How serious is flecainide toxicity?
At the severe end, flecainide toxicity can cause life-threatening arrhythmias including monomorphic ventricular tachycardia and ventricular fibrillation, complete heart block, and cardiac arrest. Death from flecainide overdose, and even from therapeutic toxicity in susceptible patients with structural heart disease, is documented.
The CAST trial established that Class IC agents including flecainide increase mortality in patients with structural heart disease. This is why the drug is avoided in those populations and why post-ablation cardiac substrate is relevant to the risk assessment.
The current presentation. CNS symptoms and chest pain, is not immediately life-threatening in the way an acute MI or severe arrhythmia is. But it is a warning signal that the drug is reaching toxic levels, and the distance between this stage and a dangerous cardiac event is not reliably large. Same-day medical contact is appropriate.
Does kidney function really affect flecainide that much?
Yes, significantly. Approximately 30% of flecainide is excreted unchanged by the kidneys, and total renal elimination accounts for a substantial portion of clearance. In patients with reduced GFR, flecainide accumulates, half-life extends, and steady-state levels rise above what the dose would produce in a patient with normal renal function.
A patient who started flecainide two years ago with normal kidney function may now have mild-to-moderate renal impairment from age or other conditions. The dose that was appropriate then can be producing toxic levels now. This is one of the most common and most missed contributors to flecainide toxicity in older patients. Any dose adjustment discussion with the electrophysiologist should include current creatinine and GFR.
Does Eliquis or Nexium interact with flecainide?
Neither causes a clinically significant interaction with flecainide. Eliquis (apixaban) has no meaningful pharmacokinetic interaction with flecainide. They operate through different pathways and do not significantly affect each other's levels.
Nexium (esomeprazole) involves mild CYP enzyme activity, but this does not produce a clinically relevant change in flecainide levels in practice. Neither medication is the explanation for toxicity symptoms, and neither needs to be stopped in the context of managing flecainide dose adjustment.
The MAP Tool maps your medication history, symptoms, and timeline to root cause. Not a diagnosis. A thread to follow.
Start Your Map